Creso Pharma
Creso Pharma
(ASX:CPH, FWB:1X8)


 

  Our Initial Entry
Price

Portfolio Initiation

5 Day VWAP
After Initiation

Current Price

Our Current Returns

ASX:CPH
$0.120
$0.000
Jan 01 2021
$0.000
$0.175
    46%
ASX:CPH
Our Current Returns
46%
View Details


Overview

Creso Pharma (ASX: CPH) utilises pharmaceutical expertise and methodological rigour to develop cannabis and hemp derived therapeutic, nutraceutical and lifestyle products with wide range patient and consumer reach for human and animal health.

In recent months, CPH has secured several purchase orders, with total POs confirmed for delivery in the first half of 2021 totalling over $1M.

The company is growing its revenue profile across a number of regions and expanding its product lines including its flagship cannaQIX® range of products, which should hopefully translate into continued momentum on the sales front.

Share price gains have also been underpinned by significant developments on the regulatory front that are likely to benefit Creso Pharma across key markets such as the US and the European Union.

In particular, US cannabis regulations are expected to open up following the Democratic Party securing the balance of power in the Senate.

The development enhances the potential for the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to be passed in the Senate, a bill which aims to remove cannabis from the US Controlled Substances Act.

Legislation like the MORE Act is expected to encourage private investors and larger corporate entities that have been hesitant to become involved in the US cannabis industry due to federal prohibition.

Creso Pharma is well positioned to capitalise on near term opportunities in the US market, with an established global distribution network that will benefit from the ruling, as well as a leading Canadian subsidiary, Mernova Medicinal Inc. (Mernova), that already has a 24,000 sq ft cannabis growing facility 220 miles from the US border that can service the US and broader markets.



Our Past Commentary on Creso Pharma


Type Date Share Price $ Title
Email 14-May-2021 $ 0.180 CPH just picked up 10 grams of pharma grade psilocybin
Email 28-Apr-2021 $ 0.210 Zero Carbon Ammonia? What happened last night?
Email 27-Apr-2021 $ 0.195 The NASDAQ Listing We Will be Watching Tonight
Email 27-Apr-2021 $ 0.195 Our Portfolio Performance from January 1st to March 31st 2020
Email 26-Mar-2021 $ 0.205 We Participated in the CPH placement - and so did Billionaire John Hancock
Email 23-Mar-2021 $ 0.220 TRIPLE DOWN ALERT - Plus 6 Hot Stocks
Email 15-Mar-2021 $ 0.220 SURPRISE: We are Now Psychedelics Investors
Article 15-Mar-2021 $ 0.220 CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company
Email 01-Mar-2021 $ 0.205 CPH deliver Financials and Confirms US Cannabis Market Entry
Article 01-Mar-2021 $ 0.205 CPH Confirms US Cannabis Market Entry with Established Partner - US$5M Sales Target
Email 19-Jan-2021 $ 0.240 The CPH Share Price Seems to Have Stabilised – What’s Next?
Article 07-Jan-2021 $ 0.195 Our Stock Picks for 2021
Article 02-Dec-2020 $ 0.046 What’s Happening to the CPH Share Price?
Email 02-Dec-2020 $ 0.046 Short Term Trade Update: What’s Happening to the CPH Share Price?
Article 13-Oct-2020 $ 0.031 Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH
Email 13-Oct-2020 $ 0.035 We are Rolling the Dice on this One…
Article 24-Mar-2020 $ 0.053 Creso’s New Immunity Boosting CBD Hemp Teas Set for Release
Article 11-Mar-2020 $ 0.071 CPH Secures Two Execs from the World’s Largest Cannabis Company
Article 04-Mar-2020 $ 0.082 Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint
Article 11-Feb-2020 $ 0.160 Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release
Article 06-Feb-2020 $ 0.155 CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough
Article 28-Jan-2020 $ 0.175 CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone
Article 21-Jan-2020 $ 0.190 CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs
Article 09-Dec-2019 $ 0.145 CPH Kick Start African Launch - $300k Order Values Confirmed
Article 03-Dec-2019 $ 0.150 Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Market Data


Latest Article

CPH just picked up 10 grams of pharma grade psilocybin

CPH just picked up 10 grams of pharma grade psilocybin

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

Related Articles

Zero Carbon Ammonia? What happened last night?

Zero Carbon Ammonia? What happened last night?

The NASDAQ Listing We Will be Watching Tonight

The NASDAQ Listing We Will be Watching Tonight

Our Portfolio Performance from January 1st to March 31st 2020

Our Portfolio Performance from January 1st to March 31st 2020

We Participated in the CPH placement - and so did Billionaire John Hancock

We Participated in the CPH placement - and so did Billionaire John Hancock

TRIPLE DOWN ALERT - Plus 6 Hot Stocks

TRIPLE DOWN ALERT - Plus 6 Hot Stocks

SURPRISE: We are Now Psychedelics Investors

SURPRISE: We are Now Psychedelics Investors

CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company

CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company

CPH deliver Financials and Confirms US Cannabis Market Entry

CPH deliver Financials and Confirms US Cannabis Market Entry

CPH Confirms US Cannabis Market Entry with Established Partner - US$5M Sales Target

CPH Confirms US Cannabis Market Entry with Established Partner - US$5M Sales Target

The CPH Share Price Seems to Have Stabilised – What’s Next?

The CPH Share Price Seems to Have Stabilised – What’s Next?

Our Stock Picks for 2021

Our Stock Picks for 2021

What’s Happening to the CPH Share Price?

What’s Happening to the CPH Share Price?

Short Term Trade Update: What’s Happening to the CPH Share Price?

Short Term Trade Update: What’s Happening to the CPH Share Price?

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

We are Rolling the Dice on this One…

We are Rolling the Dice on this One…

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

CPH Secures Two Execs from the World’s Largest Cannabis Company

CPH Secures Two Execs from the World’s Largest Cannabis Company

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

CPH Kick Start African Launch - $300k Order Values Confirmed

CPH Kick Start African Launch - $300k Order Values Confirmed

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Thanks for subscribing!

X